Roivant Sciences

Update in progress

ROIV (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and advancing medicines and delivery technologies. Its pipeline includes IMVT-1402, a human antibody targeting FcRn for various autoimmune diseases; batoclimab for thyroid eye disease; and brepocitinib, a TYK2/JAK1 inhibitor. The lead program mosliciguat is an inhaled sGC activator for pulmonary hypertension. It also offers LNP and ligand conjugate delivery platforms. Based in London, founded 2014.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.38; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.25; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive